Current Opinion in Hematology volume 18, issue 4, P288-292 2011 DOI: 10.1097/moh.0b013e32834706ee View full text
|
|
Share
John W Sweetenham

Abstract: Recent data support the concept that molecular subtyping of diffuse large B-cell lymphoma is clinically relevant and likely to be incorporated into diagnostic and therapeutic algorithms. The availability of widely applicable and reproducible techniques for determining molecular subtype will be essential.